{"id":"NCT04047472","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","officialTitle":"A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-29","primaryCompletion":"2024-02-28","completion":"2024-02-28","firstPosted":"2019-08-06","resultsPosted":"2024-12-09","lastUpdate":"2024-12-09"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Brolucizumab 6mg","otherNames":["Beovu"]},{"type":"DRUG","name":"Aflibercept 2 mg","otherNames":["Eylea"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR"}],"summary":"To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)","primaryOutcome":{"measure":"Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye","timeFrame":"Baseline, Week 48","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":9.9,"sd":0.82},{"arm":"Aflibercept 2 mg","deltaMin":10.9,"sd":0.82}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":199},"commonTop":["COVID-19","Upper respiratory tract infection","Intraocular pressure increased - Study eye","Pyrexia","Cataract - Study eye"]}}